INTENSITY THERAPEUTICS, INC. (INTS) — Institutional Holders, Q2 2026
17 institutional investment managers reported a INTS position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $4.8M. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
INTS in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- KMT WEALTH MANAGEMENTNew · +496,493 sh+$2.0M
- Kingsbury Capital Investment AdvisorsAdded · +458,439 sh+$1.9M
- FNY Investment AdvisersNew · +22,000 sh+$90.2K
- VANGUARD CAPITAL MANAGEMENTAdded · +9,728 sh+$39.9K
- SentinusAdded · +3,429 sh+$14.1K
Biggest sellers
- GEODE CAPITAL MANAGEMENTTrimmed · -3,232 sh-$13.3K
- WELLS FARGO & COMPANYSold out · -200 sh-$820.00
- UBS Group AGTrimmed · -191 sh-$783.00
INTS 13F holders ranked 1–17 of 17
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | Kingsbury Capital Investment Advisors#1 · 496,493 sh | 496,493 | $2.0M | — | +1204.7% |
| 2 | KMT WEALTH MANAGEMENT#2 · 496,493 sh | 496,493 | $2.0M | 1.72% | New |
| 3 | Sentinus#3 · 26,723 sh | 26,723 | $109.6K | <0.01% | +14.7% |
| 4 | VANGUARD CAPITAL MANAGEMENT#4 · 26,569 sh | 26,569 | $108.9K | 0.00% | +57.8% |
| 5 | SAPIENT CAPITAL#5 · 26,006 sh | 26,006 | $106.6K | — | 0.0% |
| 6 | NANO CAP NEW MILLENNIUM GROWTH FUND L P#6 · 25,000 sh | 25,000 | $102.5K | 0.08% | 0.0% |
| 7 | GEODE CAPITAL MANAGEMENT#7 · 22,787 sh | 22,787 | $93.4K | 0.00% | -12.4% |
| 8 | FNY Investment Advisers#8 · 22,000 sh | 22,000 | $90.0K | — | New |
| 9 | Mesirow Financial Investment Management#9 · 14,118 sh | 14,118 | $57.9K | <0.01% | 0.0% |
| 10 | VANGUARD FIDUCIARY#10 · 9,121 sh | 9,121 | $37.4K | 0.00% | 0.0% |
| 11 | Tower Research Capital (TRC)#11 · 1,984 sh | 1,984 | $8.1K | <0.01% | +2861.2% |
| 12 | NewEdge Advisors#12 · 1,148 sh | 1,148 | $4.7K | 0.00% | New |
| 13 | OSAIC#13 · 200 sh | 200 | $820.00 | 0.00% | 0.0% |
| 14 | BARCLAYS PLC#14 · 42 sh | 42 | $172.00 | 0.00% | New |
| 15 | MORGAN STANLEY#15 · 20 sh | 20 | $82.00 | 0.00% | 0.0% |
| 16 | Caitong International Asset Management , Ltd#16 · 6 sh | 6 | $25.00 | 0.00% | New |
| 17 | UBS Group AG#17 · 1 sh | 1 | $4.00 | 0.00% | -99.5% |
Funds that sold out of INTS in Q2 2026 (1)
Held INTS at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| WELLS FARGO & COMPANY200 sh | 200 | $1.2K |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.